Moxifloxacin and cholesterol combined treatment of pneumococcal keratitis

Current Eye Research

Volumn 35, Issue 12, 2010, Pages 1142-1147

  Sanders, Melissa E ^a   Tullos, Nathan A ^a   Taylor, Sidney D ^a   Norcross, Erin W ^a   King, Lauren B ^a   Tolo, Isaiah ^a   Marquart, Mary E ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Cholesterol; Keratitis; Moxifloxacin; Streptococcus pneumoniae

Indexed keywords

CHOLESTEROL; CHOLESTEROL PLUS MOXIFLOXACIN; MOXIFLOXACIN; MYELOPEROXIDASE; PHOSPHATE BUFFERED SALINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; COLONY FORMING UNIT; CONTROLLED STUDY; CORNEA; DISEASE SEVERITY; ENZYME ACTIVITY; HISTOPATHOLOGY; IMMUNOCOMPETENT CELL; KERATITIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PNEUMOCOCCAL KERATITIS; PRIORITY JOURNAL; RABBIT; SLIT LAMP; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CHOLESTEROL; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; KERATITIS; PEROXIDASE; QUINOLINES; RABBITS; SEVERITY OF ILLNESS INDEX; STEM CELLS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 78649745625     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2010.512114     Document Type: Article

References (22)

1. Bourcier T, Thomas F, Borderie V, et al. Bacterial keratitis: Predisposing factors, clinical and microbiological review of 300 cases. Br J Ophthalmol. 2003;87:834-838.
2. Wong T, Ormonde S, Gamble G, et al. Severe infective keratitis leading to hospital admission in New Zealand. Br J Ophthalmol. 2003;87:1103-1108.
3. Bharathi M, Ramakrishnan R, Vasu S, et al. In-vitro effcacy of antibacterials against bacterial isolates from corneal ulcers. Indian J Ophthalmol. 2002;50:109-114.
4. Donnenfeld E, O'Brien T, Solomon R, et al. Infectious keratitis after photorefractive keratectomy. Ophthalmology. 2003;110:743-747.
5. Parmar P, Salman A, Kalavathy C, et al. Pneumococcal keratitis: A clinical profle. Clin Experiment Ophthalmol. 2003;31:44-47.
6. Varaprasathan G, Miller K, Lietman T, et al. Trends in the etiology of infectious corneal ulcers at the F. I. Proctor Foundation. Cornea. 2004;23:360-364.
7. Allan BD, Dart JK. Strategies for the management of microbial keratitis. Br J Ophthalmol. 1995;79:777-786.
8. Sueke H, Kaye S, Neal T, et al. Minimum inhibitory concentrations of standard and novel antimicrobials for isolates from bacterial keratitis. Invest Ophthalmol Vis Sci. 2010;51:2519-2524.
9. Johnson M, Hobden J, Hagenah M, et al. The role of pneu-molysin in ocular infections with Streptococcus pneumoniae. Curr Eye Res. 1990;9:1107-1114.
10. Tweten RK. Cholesterol-dependent cytolysins, a fam-ily of versatile pore-forming toxins. Infect Immun. 2005;73:6199-6209.
11. Shumway CN, Klebanoff SJ. Purifcation of pneumolysin Infect Immun. 1971;4:388-392.
12. Briles DE, Nahm M, Schroer K, et al. Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 Streptococcus pneu-moniae. J Exp Med. 1981;153:694-705.
13. Marquart ME, Monds KS, McCormick CC, et al. Cholesterol as treatment for pneumococcal keratitis: Cholesterol-specifc inhibition of pneumolysin in the cornea. Invest Ophthalmol Vis Sci. 2007;48:2661-2666.
14. Nandoskar M, Ferrante A, Bates E, et al. Inhibition of human monocyte respiratory burst, degranulation, phospholipid methylation and bactericidal activity by pneumolysin Immunology. 1986;59:515-520.
15. Ferrante A, Rowan-Kelly B, Paton JC. Inhibition of in vitro human lymphocyte response by the pneumococcal toxin pneumolysin. Infect Immun. 1984;46:585-589. (Pubitemid 15204639)
16. Iliev AI, Djannatian JR, Nau R, et al. Cholesterol-dependent actin remodeling via RhoA and Rac1 activation by the Streptococcus pneumoniae toxin pneumolysin Proc Natl Acad Sci USA. 2007;104:2897-2902.
17. Iliev A, Djannatian J, Opazo F, et al. Rapid microtubule bundling and stabilization by the Streptococcus pneumoniae neurotoxin pneumolysin in a cholesterol-dependent, non-lytic and Src-kinase dependent manner inhibits intracellular traffcking. Mol Microbiol. 2009;71:461-477.
18. Watanabe I, Nomura T, Tominaga T, et al. Dependence of the lethal effect of pore-forming haemolysins of Gram-positive bacteria on cytolytic activity J Med Microbiol. 2006;55:505-510.
19. Hobden JA, Hill JM, Engel LS, et al. Age and therapeutic outcome of experimental Pseudomonas aeruginosa keratitis treated with ciprofoxacin, prednisolone, and furbiprofen Antimicrob Agents Chemother. 1993;37:1856-1859.
20. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; approved standard, seventh edition. Clinical and Laboratory Standards Institute document M7-A7. Wayne, Pennsylvania: Clinical and Laboratory Standards Institute; 2006.
21. Sanders M, Norcross E, Moore Q, et al. A comparison of pneumolysin activity and concentration in vitro and in vivo in a rabbit endophthalmitis model. Clin Ophthalmol. 2008;2:793-800.
22. Price KE, Camilli A. Pneumolysin localizes to the cell wall of Streptococcus pneumoniae. J Bacteriol. 2009;191:2163-2168.